drugset / Trial / NCT03726775
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
Phase 2
Active not recruiting
61 enrolled
Groupe Oncologie Radiotherapie Tete et Cou
Center Eugene Marquis · collabUNICANCER · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluate the regional (neck) nodal control of durvalumab in combination with RT restricted to the primary tumor and the immediately adjacent nodal level (i.e. without prophylactic neck irradiation) in N0 patients with SCCHN.
Timeline
- Start
- 2019-07-17
- Primary completion
- 2026-07
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |